

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Bono-Combie et al

Examiner: **BALLS, Robert J**

Serial No.: **10/773,073**

Art Unit: **1625**

Filed: **February 5, 2004**

Title: **USE OF 4-SUBSTITUTED
TETRAHYDROPYPRIDIENES FOR
MAKING MEDICINES ACTING ON
TGF- β 1**

TERMINAL DISCLAIMER

Commissioner for Patents
Washington, D.C. 20231
Sir:

The petitioner, Sanofi-Aventis (formerly Sanofi-Synthelabo) having offices at 174 Avenue de France, Paris FRANCE 75013, represent that they are the assignees of Application Serial No. 09/423,884, filed on April 10, 2000, by an assignment recorded at the USPTO set out in Reel 010755 Frame 0626 on April 10, 2000 and Reel 016345 Frame 0189 on July 22, 2005 (name change of Sanofi Synthelabo to Sanofi-Aventis); the above identified application Serial No. 10/773,073, filed February 5, 2004 is a division from this application.

The petitioner, Sanofi-Aventis hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of U. S. Patent No. 6,342,505, which is assigned to and commonly owned with 100 percent interest by Sanofi-Aventis (formerly Sanofi-Synthelabo and presently Sanofi-Aventis), and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to aforementioned U. S. Patent No. 6,342,505, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Such disclaimer does not, however, mean that petitioner hereby waives or disclaims any right to an extension of the term of any patent issuing from application serial number 10/773,073, under 35 USC §§ 155 to 156, pursuant to (a) Title II of Pub. L. No. 98-417, enacted on September 24, 1984, and entitled the "Drug Price Competition and Patent Term Restoration Act of 1984", (b) Pub. 98-417, enacted on September 24, 1984, and entitled the "Drug Price Competition and Patent Term Restoration Act of 1984", (b) Pub. L. No. 100-670, enacted November 16, 1988 and entitled "Patent Term Extension for Animal Drug Products", or (c) any other subsequently enacted Public Law or Act which provides for the extension of the term of a patent.

Such disclaimer does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term, as presently shortened by any terminal disclaimer of U. S. Patent No. 6,342,505 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title as stated above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please charge Deposit Account No. **18-1982** in the amount of \$130.00. The Commissioner is authorized to charge any fees under 37 CFR 1.16 - 1.21 or credit any overpayment to Account No. **18-1982**.

Signed at Bridgewater, New Jersey, U.S.A., this 17th day of July, 2007.

Respectfully submitted,



Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626